[go: up one dir, main page]

EA200500802A1 - Лечение латентного туберкулёза - Google Patents

Лечение латентного туберкулёза

Info

Publication number
EA200500802A1
EA200500802A1 EA200500802A EA200500802A EA200500802A1 EA 200500802 A1 EA200500802 A1 EA 200500802A1 EA 200500802 A EA200500802 A EA 200500802A EA 200500802 A EA200500802 A EA 200500802A EA 200500802 A1 EA200500802 A1 EA 200500802A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
hydrogen
het
formula
radical
Prior art date
Application number
EA200500802A
Other languages
English (en)
Other versions
EA009779B1 (ru
Inventor
Кунрад Йозеф Лодевейк Марсель Андрис
Анил Коул
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200500802A1 publication Critical patent/EA200500802A1/ru
Publication of EA009779B1 publication Critical patent/EA009779B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Применение соединения формулы (Ia) или (Ib) для производства лекарственного средства для лечения латентного туберкулеза, причем соединение формулы (Ia) или (Ib) представляет собойа также фармацевтически приемлемые кислотно- или основно-аддитивные соли указанных соединений, их N-оксиды, их таутомерные формы или их стереохимически изомерные формы, в которых Rпредставляет собой водород, галоген, галогеналкил, циано, гидрокси, Ar, Het, алкил, алкокси, алкилтио, алкоксиалкил, алкилтиоалкил, Ar-алкил или ди(Ar)алкил; р представляет собой целое число, равное 1, 2, 3 или 4; Rпредставляет собой водород, гидрокси, меркапто, алкокси, алкоксиалкокси, алкилтио, моно- или ди(алкил)амино или радикал формулыRпредставляет собой алкил, Ar, Ar-алкил, Het или Het-алкил; q представляет собой целое число, равное нулю, 1, 2, 3 или 4; каждый из Rи Rнезависимо представляет собой водород, алкил или бензил; или Rи R, включая также N, к которому они присоединены, могут совместно образовывать радикал; Rпредставляет собой водород, галоген, галогеналкил, гидрокси, Ar, алкил, алкокси, алкилтио, алкоксиалкил, алкилтиоалкил, Ar-алкил или ди(Ar)алкил; или два вицинальных остатка Rсовместно могут образовывать двухвалентный радикал формулы -СН=СН-СН=СН-; r представляет собой целое число, равное 1, 2, 3, 4 или 5; Rпредставляет собой водород, алкил, Ar или Het; Rпредставляет собой водород или алкил; Rпредставляет собой оксогруппу; или Rи Rсовместно образуют радикал =N-CH=CH-.
EA200500802A 2004-12-24 2005-06-09 Лечение латентного туберкулёза EA009779B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04078529 2004-12-24

Publications (2)

Publication Number Publication Date
EA200500802A1 true EA200500802A1 (ru) 2006-06-30
EA009779B1 EA009779B1 (ru) 2008-04-28

Family

ID=36736133

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500802A EA009779B1 (ru) 2004-12-24 2005-06-09 Лечение латентного туберкулёза

Country Status (9)

Country Link
JP (5) JP2006182755A (ru)
KR (2) KR101301573B1 (ru)
CN (1) CN101087608A (ru)
BG (1) BG66437B1 (ru)
EA (1) EA009779B1 (ru)
ES (1) ES2362886T3 (ru)
JO (1) JO2695B1 (ru)
UA (1) UA88766C2 (ru)
ZA (1) ZA200705160B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA97813C2 (ru) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
CN103664877A (zh) * 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
ES2934785T3 (es) * 2016-03-07 2023-02-27 Global Alliance For Tb Drug Development Inc Compuestos antibacterianos y usos de los mismos
CN109384716B (zh) * 2017-08-11 2021-06-29 海创药业股份有限公司 一种氘代喹啉化合物及其制备和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075024A (en) * 1991-11-27 2000-06-13 Sepracor Inc. Methods for treating infection using optically pure (S)-lomefloxacin
JP4484703B2 (ja) * 2002-07-25 2010-06-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用
AU2005249231B2 (en) * 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Also Published As

Publication number Publication date
JP2017141259A (ja) 2017-08-17
JO2695B1 (en) 2013-03-03
JP2015157847A (ja) 2015-09-03
KR20130041872A (ko) 2013-04-25
KR20060073416A (ko) 2006-06-28
BG109180A (bg) 2006-06-30
KR101301573B1 (ko) 2013-09-04
EA009779B1 (ru) 2008-04-28
JP2006182755A (ja) 2006-07-13
JP2017141262A (ja) 2017-08-17
ZA200705160B (en) 2008-09-25
ES2362886T3 (es) 2011-07-14
JP6426530B2 (ja) 2018-11-21
UA88766C2 (ru) 2009-11-25
JP2013049704A (ja) 2013-03-14
BG66437B1 (bg) 2014-07-31
CN101087608A (zh) 2007-12-12

Similar Documents

Publication Publication Date Title
MY145845A (en) Treatment of latent tuberculosis
NO20080955L (no) Kinolinderivater som antibakterielle midler
NO20081026L (no) Kinolinderivater som antibakterielle midler
NO20080499L (no) Kinolinderivater som antibakterielle midler
NO20081068L (no) Kinolinderivater som antibakterielle midler
CA2559128A1 (en) Kinase inhibitors
NO20080501L (no) Kinolinderivater som antibakterielle midler
WO2005070924A8 (en) Substituted quinolines and their use as mycobacterial inhibitors
EA200500802A1 (ru) Лечение латентного туберкулёза
NO20080481L (no) Kinolinderivater som antibakterielle midler
TW200942538A (en) 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof